Goldenseal for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Goldenseal for Health & Longevity

Created on 06/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A North American herb whose root contains plant compounds called alkaloids, chiefly berberine. Its strongest human evidence is not that it treats anything, but that it lowers the activity of liver drug-processing systems by roughly half, raising the levels of many medicines. Evidence for benefit is very low; it should be avoided in pregnancy, breastfeeding, newborns, and with narrow-margin drugs. (Full Review)

Protocol

Standard Traditional Approach
Dried root ~0.5–1 g three times daily
Or tincture (1:10 in ~60% alcohol) ~2–4 mL three times daily, or standardized extract dosed to alkaloid content; short courses for acute complaints, not continuous use.
Single vs. Split Dosing
Split dosing, two to three times daily
Consistent with short alkaloid plasma persistence and to limit gastrointestinal irritation per dose.
Best Time of Day
No timing established; taken with food
Traditional use spreads doses through the day; taking with food may reduce stomach upset.
Time to effect
Traditional Acute Uses
Within days
For digestive upset and mucosal irritation, any effect would be expected within days.
Systemic / Longevity Benefits
No established timeline
No timeline exists because none are demonstrated.

Benefits

Contraindications
  • Pregnancy (any trimester) and breastfeeding
  • Newborns and neonates
  • Narrow-therapeutic-index CYP3A4/CYP2D6 drugs (e.g., transplant recipients on cyclosporine or tacrolimus, certain antiarrhythmics)
  • Significant liver disease (e.g., Child-Pugh Class B or C)
    •
Key Interactions
  • Prescription CYP3A4 substrates (e.g., felodipine, nifedipine, simvastatin, atorvastatin, midazolam, triazolam, cyclosporine, tacrolimus)
  • CYP2D6 substrates (e.g., fluoxetine, paroxetine, metoprolol, codeine, tramadol)
  • OTC CYP3A4/CYP2D6 substrates (e.g., dextromethorphan, certain pain relievers)
  • CYP3A4-inhibiting botanicals (e.g., grapefruit-derived products)
  • Berberine-containing supplements (e.g., barberry, Oregon grape, Chinese goldthread) and blood-sugar-lowering supplements (e.g., cinnamon, alpha-lipoic acid)
  • Metformin
    •

Risk & Side Effects

  • High: Drug-metabolism interactions
    •
  • Medium: Avoidance in pregnancy and lactation
    •
  • Low: Gastrointestinal upset and mucosal irritation
    •
  • Speculative: Phototoxicity of alkaloids; hepatic and neurological effects
    •

Monitoring

Marker Target Why
ALT (alanine aminotransferase) ~10–26 U/L Detects liver stress from alkaloids or affected drugs
AST (aspartate aminotransferase) ~10–26 U/L Complements ALT for liver-cell injury
Total and direct bilirubin Total <1.0 mg/dL Flags impaired bilirubin handling (kernicterus mechanism)
Interacting drug level (e.g., tacrolimus, cyclosporine, digoxin) Within the drug's own therapeutic window Goldenseal can raise levels of CYP3A4/CYP2D6 substrates
Fasting glucose 70–85 mg/dL Detects additive blood-sugar lowering from the berberine fraction

Cadence: Baseline before starting; when co-medicated, at 1–2 weeks after starting, again if the dose changes, and after stopping. Short standalone courses in healthy adults generally need no formal lab monitoring.

Qualitative Assessment

  • Gastrointestinal comfort (nausea, cramping, or irritation as dose-limiting signs)
  • Energy levels and any unusual fatigue (possible signal of altered drug levels)
  • Resolution of the acute complaint being self-treated (e.g., digestive symptoms)
  • Any new side effects from existing medications (a clue to an interaction)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.